Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Plain-English Summary
This study looked at a medication called setmelanotide to help with weight management in people with Bardet-Biedl Syndrome (BBS). The researchers compared 29 patients who took setmelanotide for one year with 58 similar patients who didn't receive the treatment. They wanted to see if the medication helped people lose weight or have healthier weight measurements. The results were very promising. About 59% of patients taking setmelanotide had meaningful weight improvements, compared to only 7% of those not taking it. The medication worked especially well in children - 71% showed improvement compared to just 11% of children not on the treatment. Adults also benefited, though not quite as much, with 47% showing improvement versus only 3% of adults not taking the medication. This research is important because it provides strong evidence that setmelanotide can help manage the weight problems that are common in BBS. Since this was a one-year study of an actual treatment (not just laboratory research), it gives families and doctors good information about whether this medication might help. The drug appears to be a real option for helping people with BBS achieve healthier weights, which could improve their overall health and quality of life.
Original Abstract
This analysis aimed to assess the efficacy of setmelanotide over 52 weeks in patients with Bardet-Biedl syndrome (BBS) compared with an external natural history cohort from the international Clinical Registry Investigating BBS (CRIBBS). Patients with BBS ≥ 6 years of age (n = 29) treated with setmelanotide for 52 weeks in a phase 3 trial (NCT03746522) and a propensity-score matched external control cohort (n = 58) from CRIBBS were included. Responder rate at week 52 was defined as ≥ 0.3-point decrease in BMI z-score (patients ≤ 18 years) or ≥ 10% body weight reduction (adults). Secondary outcomes included changes in BMI, BMI z-score, and body weight. A significantly greater proportion of patients treated with setmelanotide met the primary endpoint compared with control patients (58.6% vs. 6.9%; p < 0.001). In pediatric patients, 71.4% achieved the primary endpoint vs. 10.7% of controls (p < 0.001); in adults, corresponding numbers were 46.7% vs. 3.3% (p = 0.001). Secondary outcomes demonstrated consistent benefits of setmelanotide treatment. Sensitivity analysis using inverse probability of treatment weighting confirmed these findings. This indirect comparison provides additional strong evidence that setmelanotide significantly improves weight outcomes in patients with BBS. These findings further support its clinical benefit over 52 weeks in managing obesity associated with BBS. ClinicalTrials.gov identifier: NCT03746522.